<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074368</url>
  </required_header>
  <id_info>
    <org_study_id>202106039MINA</org_study_id>
    <nct_id>NCT05074368</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination</brief_title>
  <official_title>Comparative Analysis of Neutralizing Antibody Response Among Heterologous ChAdOx1-nCov-19/mRNA-1273 Vaccination and Homologous ChAdOx1-nCov-19 or Homologous mRNA-1273 Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taoyuan General Hospital, Ministry of Health and Welfare,Taoyuan,Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct a prospective analysis to compare homologous and heterologous&#xD;
      adenovirus vector ChAdOx1-nCov-19 (Astra-Zeneca) or SARS-CoV-2 messenger RNA-1273 (Moderna)&#xD;
      vaccine inoculation. Healthy volunteers will be enrolled and divided into five groups. The&#xD;
      first group is the subjects who received ChAdOx1- nCov-19 vaccine with 8 weeks apart; the&#xD;
      second group is the SARS-CoV-2 messenger RNA-1273 vaccine after the first dose of&#xD;
      ChAdOx1-nCov-19 vaccination with 8 weeks apart; the third group is the first dose of&#xD;
      ChAdOx1-nCov-19 vaccine and the SARS-CoV-2 messenger RNA-1273 vaccine with 4 weeks apart; the&#xD;
      fourth group is the SARS-CoV-2 messenger RNA-1273 vaccination with 4 weeks apart; the fifth&#xD;
      group is the first dose of ChAdOx1-nCov-19 vaccine and the SARS-CoV-2 messenger RNA-1273&#xD;
      vaccine with 12 weeks apart. There will be 100 volunteers in each group. Antibody test on the&#xD;
      day before and the 14th, 28th day and 12th week after the second dose of vaccination,&#xD;
      including 100 subjects in each group for SARS-CoV-2 ELISA antibody titer and 50 people in&#xD;
      each group for SARS-CoV-2 neutralizing antibody titer. Adverse reactions at the first day,&#xD;
      the 14th day, the 28th day, and the 12th week. The research team follow up each volunteer at&#xD;
      the 6th month.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators would like to conduct a prospective analysis to compare the same adenovirus&#xD;
      vector ChAdOx1-nCov-19 (Astra-Zeneca) or SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine&#xD;
      inoculation and mixed inoculation of ChAdOx1-nCov-19 and messenger RNA-1273 vaccine. Healthy&#xD;
      volunteers (including medical personnel) will be enrolled and divided into five groups&#xD;
      according to their wishes. The five groups are: the first group is the subjects who received&#xD;
      ChAdOx1- nCov-19 vaccine with 8 weeks apart; the second group is the SARS-CoV-2 messenger&#xD;
      RNA-1273 vaccine after the first dose of ChAdOx1-nCov-19 vaccination with 8 weeks apart; the&#xD;
      third group is the first dose of ChAdOx1-nCov-19 vaccine and the SARS-CoV-2 messenger&#xD;
      RNA-1273 vaccine with 4 weeks apart; the fourth group is the SARS-CoV-2 messenger RNA-1273&#xD;
      vaccination with 4 weeks apart; the fifth group is the first dose of ChAdOx1-nCov-19 vaccine&#xD;
      and the SARS-CoV-2 messenger RNA-1273 vaccine with 12 weeks apart. There will be 100&#xD;
      volunteers in each group, and blood will be drawn for antibody test on the day before and the&#xD;
      14th, 28th day and 12th week after the second dose of vaccination, including 100 subjects in&#xD;
      each group for SARS-CoV-2 ELISA antibody titer and 50 people in each group for SARS-CoV-2&#xD;
      neutralizing antibody titer. This study analyzo the titers of SARS-CoV-2 antibodies, and&#xD;
      records adverse reactions at each visits including the first day, the 14th day, the 28th day,&#xD;
      and the 12th week (including those within 7 days after the inoculation). Adverse reactions&#xD;
      and whether there is development of COVID-19 within 6 months will be recorded. The research&#xD;
      team will also follow up by phone in the 6th month to ask whether there is vaccine associated&#xD;
      adverse events or SARS-CoV-2 infection. The results will provide information for vaccine&#xD;
      policy in Taiwan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Samples for by using enzyme-linkes immuno sorbent assay (ELISA) at 14th,28th,12 th week and 6 months after the second dose.</measure>
    <time_frame>1 years</time_frame>
    <description>Neutralizing antibody response among heterologous and heterologous COVID-19 vaccination and homologous</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Sample for spike-specific CD4+ T cells</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Sample for production of interferon(IFN)-γ</measure>
    <time_frame>6 months</time_frame>
    <description>(pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Sample for tumor necrosis factor (TNF)-α</measure>
    <time_frame>6 months</time_frame>
    <description>(pg/mL)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse events and severe adverse events at 14th,28th,12 th week and 6months after the second dose.</description>
  </other_outcome>
  <other_outcome>
    <measure>severe adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse events and severe adverse events at 14th,28th,12 th week and 6months after the second dose.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Healthy Adult Volunteers</condition>
  <arm_group>
    <arm_group_label>Heterologous ChAdOx1-nCov-19 vaccination - 8 weeks apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Astra-Zeneca vaccine 0.5 mL/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mRNA-1273 Vaccination and Heterologous ChAdOx1-nCov-19 vaccination- 8 weeks apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination- 4 weeks apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The mRNA-1273 Vaccination- 4 weeks apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderna COVID-19 Vaccine 0.5 mL/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination-12 weeks apart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAdOx1-nCov-19 (Astra-Zeneca)</intervention_name>
    <description>vaccine inoculation and mixed inoculation</description>
    <arm_group_label>Heterologous ChAdOx1-nCov-19 vaccination - 8 weeks apart</arm_group_label>
    <arm_group_label>Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination- 4 weeks apart</arm_group_label>
    <arm_group_label>Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination-12 weeks apart</arm_group_label>
    <arm_group_label>mRNA-1273 Vaccination and Heterologous ChAdOx1-nCov-19 vaccination- 8 weeks apart</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine</intervention_name>
    <description>vaccine inoculation and mixed inoculation</description>
    <arm_group_label>Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination- 4 weeks apart</arm_group_label>
    <arm_group_label>Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination-12 weeks apart</arm_group_label>
    <arm_group_label>The mRNA-1273 Vaccination- 4 weeks apart</arm_group_label>
    <arm_group_label>mRNA-1273 Vaccination and Heterologous ChAdOx1-nCov-19 vaccination- 8 weeks apart</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females aged ≥20 to &lt;65 years old and have received adenovirus vector vaccine&#xD;
             ChAdOx1-nCov-19 (Astra-Zeneca) or SARS-CoV-2 messenger RNA-1273 once within three&#xD;
             months at least four weeks apart.&#xD;
&#xD;
          2. The subject must sign the subject's inform consent, or the subject's legal&#xD;
             representative must understand and agree, then sign inform consent according to&#xD;
             procedure above.&#xD;
&#xD;
          3. Healthy or existing medical condition is stable, and within 3 months before being&#xD;
             included in the trial, he or she has not been hospitalized due to illness, and his or&#xD;
             her condition is expected to remain stable during the trial period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Are currently pregnant or breastfeeding or plan to become pregnant within 30 days&#xD;
             after the second dose of the trial vaccine.&#xD;
&#xD;
          2. Currently receiving or receiving other vaccines, including Streptococcus pneumoniae&#xD;
             vaccine.&#xD;
&#xD;
          3. Have used any blood products or intravenous immunoglobulin within 12 weeks before&#xD;
             entering the test. Receive concurrent immunosuppressive or immunomodulatory therapy&#xD;
             (including steroid prednisone, targeted drugs such as infliximab, adalimumab,&#xD;
             etanercept) within 12 weeks.&#xD;
&#xD;
          4. Immunosuppressive diseases or immune insufficiency states, including hematological&#xD;
             malignancies, parenchymal organs, bone marrow transplant history or asplenia,&#xD;
             autoimmune diseases (systemic lupus, rheumatoid arthritis, scleroderma, polyarthritis,&#xD;
             autoimmune thyroiditis, etc.) and human immunodeficiency virus infection.&#xD;
&#xD;
          5. Bleeding disease and assessed as a contraindication to prohibit the use of&#xD;
             intramuscular injection or blood draw.&#xD;
&#xD;
          6. Other condition, such as physical examination or instability according to the trial&#xD;
             investigator's judgment, or participation in this trial may adversely affect the&#xD;
             safety of subjects, fail to comply with trial regulations, or interfere with trial&#xD;
             evaluation indicators.&#xD;
&#xD;
          7. The subject is known to have been infected with severe acute respiratory syndrome&#xD;
             coronavirus type 2 (SARS-CoV-2).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Both gender allowed</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <state>X</state>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenovirus-vector ChAdOx1 vaccination</keyword>
  <keyword>messenger RNA (mRNA-1273 )vaccination</keyword>
  <keyword>Coronavirus disease 2019 (COVID-19)</keyword>
  <keyword>humoral immunity</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>adverse events</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

